Luxturna, a one-shot retina treatment, can be prescribed at general hospitals. According to related industries, Luxturna, a treatment for Inherited Retinal Dystrophy, has passed the drug committee of medical institutions such as Seoul National University Hospital.

Luxturna is currently in the process of registering for insurance benefits and is beginning to create a prescription environment. This drug passed HIRA on the 7th and is about to negotiate the price with NHIS. Discussions on reimbursement for Luxturna, which is an expensive drug and targets a very small number of patients, were difficult. An application for benefits was submitted in September 2021, but there has been no significant progress in